April 27, 2018 / 6:33 AM / 5 months ago

BRIEF-Celyad's CYAD-01 Induced Complete Remission In Relapsed/Refractory AML Patient

April 27 (Reuters) - CELYAD SA:

* HAEMATOLOGICA PUBLISHES CELYAD THINK STUDY CASE REPORT OF CYAD-01 INDUCED COMPLETE REMISSION IN RELAPSED/REFRACTORY AML PATIENT

* PATIENT ACHIEVED A COMPLETE MOLECULAR REMISSION AND REMAINS IN REMISSION 9 MONTHS POST STUDY ENROLLMENT

* CYAD-01 WAS WELL TOLERATED WITH NO SIGNIFICANT TOXICITIES

* DEMONSTRATED 1ST OBJECTIVE RESPONSE TO ANY CAR-T IN RELAPSED/REFRACTORY AML WITHOUT PRECONDITIONING CHEMOTHERAPY HIGHLIGHTS POTENTIAL OF CYAD-01 AS TREATMENT FOR AML Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below